Robert Wasserman
Stock Analyst at Benchmark
(2.14)
# 1,531
Out of 4,412 analysts
69
Total ratings
40.98%
Success rate
-5.92%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Reiterates: Buy | $130 | $109.58 | +18.63% | 4 | Apr 26, 2024 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $50 | $38.57 | +29.63% | 5 | Apr 16, 2024 | |
| LGND Ligand Pharmaceuticals | Reiterates: Buy | $95 | $70.57 | +34.62% | 6 | Apr 12, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $5 | $1.92 | +160.42% | 9 | Apr 11, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $4.48 | +78.57% | 4 | Mar 22, 2024 | |
| INTS Intensity Therapeutics | Reiterates: Speculative Buy | $12 | $3.93 | +205.73% | 4 | Mar 21, 2024 | |
| IPA ImmunoPrecise Antibodies | Reiterates: Speculative Buy | $5 | $1.32 | +278.79% | 4 | Mar 15, 2024 | |
| NEPH Nephros | Upgrades: Speculative Buy | $5 | $2.19 | +128.31% | 1 | Mar 8, 2024 | |
| ATHE Alterity Therapeutics | Reiterates: Speculative Buy | $4 | $2.51 | +59.36% | 1 | Mar 7, 2024 | |
| PCSA Processa Pharmaceuticals | Reiterates: Speculative Buy | $4 | $2.15 | +86.05% | 1 | Mar 6, 2024 | |
| CDXS Codexis | Upgrades: Buy | $9 | $2.66 | +238.35% | 4 | Feb 29, 2024 | |
| ABCL AbCellera Biologics | Upgrades: Buy | n/a | $3.76 | - | 3 | Feb 22, 2024 | |
| RGEN Repligen | Downgrades: Hold | n/a | $166.58 | - | 2 | Dec 4, 2023 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.70 | +195.90% | 4 | Oct 3, 2023 | |
| TECH Bio-Techne | Reiterates: Buy | $120 | $64.06 | +87.32% | 3 | Aug 18, 2023 | |
| PRLB Proto Labs | Reiterates: Buy | $45 | $31.37 | +43.45% | 5 | May 26, 2023 | |
| FBIO Fortress Biotech | Reiterates: Speculative Buy | $75 | $1.72 | +4,260.47% | 2 | Apr 6, 2023 | |
| DHR Danaher | Downgrades: Hold | n/a | $246.58 | - | 3 | Oct 24, 2022 | |
| BLFS BioLife Solutions | Downgrades: Hold | n/a | $17.53 | - | 4 | May 14, 2021 |
Integer Holdings
Apr 26, 2024
Reiterates: Buy
Price Target: $130
Current: $109.58
Upside: +18.63%
Halozyme Therapeutics
Apr 16, 2024
Reiterates: Buy
Price Target: $50
Current: $38.57
Upside: +29.63%
Ligand Pharmaceuticals
Apr 12, 2024
Reiterates: Buy
Price Target: $95
Current: $70.57
Upside: +34.62%
Emergent BioSolutions
Apr 11, 2024
Reiterates: Buy
Price Target: $5
Current: $1.92
Upside: +160.42%
OmniAb
Mar 22, 2024
Reiterates: Buy
Price Target: $8
Current: $4.48
Upside: +78.57%
Intensity Therapeutics
Mar 21, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $3.93
Upside: +205.73%
ImmunoPrecise Antibodies
Mar 15, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.32
Upside: +278.79%
Nephros
Mar 8, 2024
Upgrades: Speculative Buy
Price Target: $5
Current: $2.19
Upside: +128.31%
Alterity Therapeutics
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $2.51
Upside: +59.36%
Processa Pharmaceuticals
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $2.15
Upside: +86.05%
Codexis
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $2.66
Upside: +238.35%
AbCellera Biologics
Feb 22, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.76
Upside: -
Repligen
Dec 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $166.58
Upside: -
Anebulo Pharmaceuticals
Oct 3, 2023
Reiterates: Speculative Buy
Price Target: $8
Current: $2.70
Upside: +195.90%
Bio-Techne
Aug 18, 2023
Reiterates: Buy
Price Target: $120
Current: $64.06
Upside: +87.32%
Proto Labs
May 26, 2023
Reiterates: Buy
Price Target: $45
Current: $31.37
Upside: +43.45%
Fortress Biotech
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.72
Upside: +4,260.47%
Danaher
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $246.58
Upside: -
BioLife Solutions
May 14, 2021
Downgrades: Hold
Price Target: n/a
Current: $17.53
Upside: -